248 related articles for article (PubMed ID: 37633973)
1. FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner.
Kim JW; Kim MJ; Han TH; Lee JY; Kim S; Kim H; Oh KJ; Kim WK; Han BS; Bae KH; Ban HS; Bae SH; Lee SC; Lee H; Lee EW
Cell Death Dis; 2023 Aug; 14(8):567. PubMed ID: 37633973
[TBL] [Abstract][Full Text] [Related]
2. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers.
Koppula P; Lei G; Zhang Y; Yan Y; Mao C; Kondiparthi L; Shi J; Liu X; Horbath A; Das M; Li W; Poyurovsky MV; Olszewski K; Gan B
Nat Commun; 2022 Apr; 13(1):2206. PubMed ID: 35459868
[TBL] [Abstract][Full Text] [Related]
3.
Emmanuel N; Li H; Chen J; Zhang Y
Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074
[TBL] [Abstract][Full Text] [Related]
4. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin synergizes with PRLX93936 to induce ferroptosis in non-small cell lung cancer cells.
Liang Z; Zhao W; Li X; Wang L; Meng L; Yu R
Biochem Biophys Res Commun; 2021 Sep; 569():79-85. PubMed ID: 34237431
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
9. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
10. Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer.
Lee J; Roh JL
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166788. PubMed ID: 37302427
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
13. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
[TBL] [Abstract][Full Text] [Related]
14. Autophagy Inhibition Plays a Protective Role in Ferroptosis Induced by Alcohol via the p62-Keap1-Nrf2 Pathway.
Zhao Y; Lu J; Mao A; Zhang R; Guan S
J Agric Food Chem; 2021 Aug; 69(33):9671-9683. PubMed ID: 34388345
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
16. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
17.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin induces ferroptosis via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells.
Cai S; Ding Z; Liu X; Zeng J
Chem Biol Interact; 2023 Jan; 369():110262. PubMed ID: 36396105
[TBL] [Abstract][Full Text] [Related]
19. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
